Edition:
United Kingdom

People: Invacare Corp (IVC.N)

IVC.N on New York Stock Exchange

16.35USD
23 May 2018
Change (% chg)

$-0.20 (-1.21%)
Prev Close
$16.55
Open
$16.50
Day's High
$16.50
Day's Low
$16.30
Volume
47,894
Avg. Vol
63,862
52-wk High
$19.20
52-wk Low
$11.25

Monaghan, Matthew 

Mr. Matthew E. Monaghan is Chairman of the Board, President, Chief Executive Officer of the Company. Prior to joining Invacare, Mr. Monaghan served as a business unit leader at Zimmer Holdings (now Zimmer Biomet NYSE: ZBH), a major orthopedic implant company, serving first as Vice President and General Manager of the company’s Global Hips business (December 2009 to January 2014) and later as Senior Vice President of Hips and Reconstructive Research (January 2014 until joining Invacare). While at Zimmer, Mr. Monaghan was responsible for the Hip division’s new product development, engineering, marketing, clinical studies, quality, regulatory affairs and results of the shared sales and supply chain functions. Later, those responsibilities also included directing global research for various areas of material, process and product innovation. Prior to joining Zimmer in 2009, Mr. Monaghan spent eight years as an operating executive for two leading private equity firms, Texas Pacific Group (TPG) and Cerberus Capital Management, where he led acquisitions and operational improvements of portfolio companies, which included the carve-out from Baxter Healthcare of a global medical business, making significant improvements at a U.S. personal insurance business and as COO of a consumer durable goods business spun off from Newell-Rubbermaid. For the first 13 years of his career, Mr. Monaghan held various engineering, financial and management positions at General Electric (NYSE:GE). Since November 2016, Mr. Monaghan has served as a director of INC Research (NASDAQ: INCR), a contract research organization serving the needs of pharmaceutical clients.

Basic Compensation

Total Annual Compensation, USD 933,300
Restricted Stock Award, USD 3,107,950
Long-Term Incentive Plans, USD --
All Other, USD 50,368
Fiscal Year Total, USD 4,091,620

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --